(RTTNews) - Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary ...
Biohaven Pharmaceutical Holding Company logo is displayed on screen on floor of NYSE in New York (Reuters) -Biohaven Pharmaceutical Holding Co Ltd said on Monday its drug candidate, verdiperstat, ...
A Biohaven Pharmaceuticals drug acquired from AstraZeneca has failed a pivotal study testing it as a treatment for the rare neurodegenerative disease multiple system atrophy. The drug, verdiperstat, ...
(MENAFN- GetNews) The Key Multiple System Atrophy Companies in the market include - Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis ...
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Owning big U.S. tech stocks is once again the most popular trade, according to BofA's monthly fund manager survey, as upbeat earnings and improved sentiment towards the global economy send investors ...
Sept 27 (Reuters) - Biohaven Pharmaceutical Holding Co Ltd (BHVN.N), opens new tab said on Monday its drug candidate, verdiperstat, failed to show effectiveness in treating a rare neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback